Press coverage about Puma Biotechnology (NASDAQ:PBYI) has trended somewhat positive recently, Accern Sentiment reports. The research firm rates the sentiment of news coverage by monitoring more than twenty million news and blog sources in real-time. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. Puma Biotechnology earned a news impact score of 0.15 on Accern’s scale. Accern also assigned news articles about the biopharmaceutical company an impact score of 47.414925947771 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the immediate future.
These are some of the media stories that may have effected Accern Sentiment Analysis’s scoring:
NASDAQ PBYI traded down $2.00 on Friday, reaching $62.80. The stock had a trading volume of 630,018 shares, compared to its average volume of 603,381. The company has a current ratio of 1.82, a quick ratio of 1.79 and a debt-to-equity ratio of 0.91. Puma Biotechnology has a 12-month low of $28.35 and a 12-month high of $136.90. The stock has a market cap of $2,368.82, a P/E ratio of -8.00 and a beta of 0.15.
Puma Biotechnology (NASDAQ:PBYI) last issued its quarterly earnings data on Thursday, March 1st. The biopharmaceutical company reported ($1.71) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($1.98) by $0.27. The firm had revenue of $21.60 million during the quarter, compared to analysts’ expectations of $20.83 million. During the same quarter in the prior year, the firm posted ($1.22) EPS. research analysts predict that Puma Biotechnology will post -4.07 earnings per share for the current year.
PBYI has been the subject of several recent analyst reports. Credit Suisse Group decreased their target price on Puma Biotechnology from $147.00 to $106.00 and set an “outperform” rating for the company in a research note on Wednesday, January 24th. BidaskClub cut Puma Biotechnology from a “buy” rating to a “hold” rating in a research note on Friday, January 26th. JPMorgan Chase decreased their target price on Puma Biotechnology from $138.00 to $91.00 and set a “buy” rating for the company in a research note on Wednesday, January 24th. Bank of America decreased their target price on Puma Biotechnology from $135.00 to $115.00 and set a “buy” rating for the company in a research note on Wednesday, January 24th. Finally, Royal Bank of Canada decreased their target price on Puma Biotechnology to $77.00 and set a “sector perform” rating for the company in a research note on Wednesday, January 24th. One analyst has rated the stock with a sell rating, four have given a hold rating and seven have given a buy rating to the company’s stock. The stock presently has an average rating of “Buy” and an average price target of $103.11.
In other news, insider Alan H. Auerbach sold 10,692 shares of the business’s stock in a transaction that occurred on Monday, January 22nd. The stock was sold at an average price of $92.75, for a total value of $991,683.00. Following the transaction, the insider now owns 4,155,931 shares of the company’s stock, valued at $385,462,600.25. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, SVP Richard Paul Bryce sold 1,860 shares of the business’s stock in a transaction that occurred on Monday, January 22nd. The shares were sold at an average price of $92.75, for a total value of $172,515.00. Following the completion of the transaction, the senior vice president now directly owns 25,379 shares in the company, valued at approximately $2,353,902.25. The disclosure for this sale can be found here. 21.10% of the stock is currently owned by insiders.
ILLEGAL ACTIVITY WARNING: “Puma Biotechnology (PBYI) Given Daily Media Sentiment Rating of 0.15” was originally published by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this piece of content on another publication, it was stolen and republished in violation of US and international copyright and trademark laws. The correct version of this piece of content can be read at https://www.dispatchtribunal.com/2018/04/08/somewhat-favorable-news-coverage-somewhat-unlikely-to-impact-puma-biotechnology-pbyi-share-price.html.
Puma Biotechnology Company Profile
Puma Biotechnology, Inc is a biopharmaceutical company that focuses on the development and commercialization of products for the treatment of cancer. The Company focuses on in-licensing the development and commercialization rights to over three drug candidates, including PB272 (neratinib (oral)), PB272 (neratinib (intravenous)) and PB357.
Receive News & Ratings for Puma Biotechnology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Puma Biotechnology and related companies with MarketBeat.com's FREE daily email newsletter.